Non-alcoholic Steatohepatitis Biomarkers Market
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market was valued US$ Bn in 2019 and is expected to reach US$ Bn by 2027, at a % CAGR of around % during a forecast period.
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market
Nonalcoholic steatohepatitis (NASH) is the active form of Nonalcoholic fatty liver disease (NAFLD), with hepatic necroinflammation and faster fibrosis progression. The unwanted fat deposition in liver is the key cause of this disease. If left untreated or undiagnosed, it can lead to liver cirrhosis and ultimately progress to liver failure. The high incidence of liver-related diseases has encourage some industry players and research institutes to spend in development of sophisticated NASH diagnostic and therapeutic products.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
The scope of the report includes a detailed study of global and regional markets for Non-alcoholic Steatohepatitis (NASH) Biomarkers with the reasons given for variants in the growth of the industry in certain regions.
The prevalence of NASH is rising at a shocking rate and thus has directed to the increasing need for effective diagnostic tools in recent years. The NASH Education Program reported that, the incidence of NASH is expected to increase by XX% during 2015 to 2027. The rising incidence of diabetes and obesity, increasing demand for non-invasive tests, and increasing public and private sector initiatives to upsurge awareness about NASH are anticipated to drive the growth of the market. Apart from this, the negative regulatory scenario is expected to affect market growth during forecast period. For example, the existence of stringent regulations by the US FDA for the limitation of biomarkers is expected to restrict the market growth.
The report on Non-alcoholic Steatohepatitis (NASH) Biomarkers market covers segments such as Marker Type, End User and Region. The Marker Type segment includes Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others. Among the Marker Type, Serum Biomarkers is accounted for the largest XX% market share in the Non-alcoholic Steatohepatitis (NASH) Biomarkers market, due to their indirect relation with NASH. The Hepatic fibrosis markers are anticipated to raise exponentially during forecasted period due to their more accuracy and efficiency. This marker type segment is anticipated to hold the leading share of NASH biomarkers market by 2027. The End User segment is further sub-segmented into Pharmaceutical Companies and CROs, Research Institutes and Academics, Hospitals & Clinics, Diagnostic Centers, and Others. Because of the necessity of non-invasive diagnostic tools for routine observing of drug therapy efficiency in the course of clinical trial of drug candidates, the Pharmaceutical Companies and CROs end-user segment is anticipated to have a reasonable growth during the forecasted period.
Scope of the Non-alcoholic Steatohepatitis (NASH) Biomarkers Market
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By Marker Type
â€¢ Serum Biomarkers
â€¢ Hepatic Fibrosis Biomarkers
â€¢ Apoptosis Biomarkers
â€¢ Oxidative Stress Biomarkers
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By End User
â€¢ Pharmaceutical Companies and CROs
â€¢ Research Institutes and Academics
â€¢ Hospitals & Clinics
â€¢ Diagnostic Centers
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By Region
â€¢ North America
â€¢ Asia Pacific
â€¢ Middle East & Africa
â€¢ South America
Key players operating in the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market
Author Signature :